ONGLYZA LAWSUIT

ONGLYZA LAWSUIT Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) belong to a new class of diabetic drugs known as DPP-4 inhibitors. Onglyza gained federal drug approval by the U.S. Food & Drug Administration (FDA) despite initial concerns over the cardiovascular safety of the drug. These concerns were echoed in a post-marketing safety study that found Onglyza may be associated with an increased risk of heart failure and an increased risk of death. If you or a loved one took Onglyza as directed and suffered from Onglyza side effects including heart failure or other cardiovascular injuries—such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Onglyza lawyer Timothy L. Miles today to see if you are eligible for a Onglyza lawsuit and possibly entitled to substantial compensation. https://www.classactionlawyertn.com/onglyza.html Follow us: https://www.facebook.com/timmileslaw https://twitter.com/TimMile83043830 https://www.linkedin.com/company/the-law-offices-of-timothy-l-miles https://www.youtube.com/channel/UCbEh7RkQ94C6KVlZGubIYmQ https://www.pinterest.com/tmiles676767/ https://www.instagram.com/10k_law/1

from
https://www.youtube.com/watch?v=PXIpHEy15PY